INMB vs KMB · rev $50.0K vs P/E 19, rev $8.35B
INmune Bio Inc (INMB) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
INMB currently screens at market cap $33.5M. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the INMB and KMB stock pages for the full models.
Not investment advice.